Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Genio Technologies
AddedFeb 16, 2024
UpdatedJun 18, 2026
Genio Technologies

Genio Technologies

Cancer diagnostic provider using a handheld device, the MasSpec Pen, for rapid, non-destructive tumor detection.

HQ
Tulsa, OK, US
Founded
2019
Overview
Compare
Fundraising
Employees

Genio Technologies is a cancer diagnostic provider focused on revolutionizing tumor detection with its innovative product, the MasSpec Pen. This handheld device rapidly identifies the molecular profile of tissues using a small water droplet and mass spectrometry analysis. Within seconds, it provides a diagnosis with an associated probability of cancer presence, leveraging machine learning algorithms for accuracy.

The MasSpec Pen's non-destructive approach offers significant advancements in medical diagnostics, aiming to improve patient outcomes through quicker and more precise cancer detection. This technology has the potential to transform surgical procedures and diagnostic practices, making significant strides in the healthcare industry.

Genio Technologies - Similar Companies

Torpedo Diagnostics logo

Torpedo Diagnostics

Cellens logo

Cellens

cellensinc.com

Breath Diagnostics logo

Breath Diagnostics

Digistain logo

Digistain

digistain.co.uk

Droplet Biosciences logo

Droplet Biosciences

dropletbiosci.com

Liquid Genomics logo

Liquid Genomics

AccuraGen logo

AccuraGen

Vocxi Health logo

Vocxi Health

KinaSense logo

KinaSense

Cleveland Diagnostics logo

Cleveland Diagnostics

clevelanddx.com

Genendeavor logo

Genendeavor

genendeavor.com

Malcova logo

Malcova

Aeena Dx logo

Aeena Dx

Prompt Diagnostics logo

Prompt Diagnostics

prompt-dx.com

Clear Gene logo

Clear Gene

cleargene.com

Genio Technologies - Quick Facts

Who are Genio Technologies' competitors?

Companies similar to Genio Technologies include Torpedo Diagnostics, Cellens, Breath Diagnostics and Digistain.

When was Genio Technologies founded?

Genio Technologies was founded in 2019.

Where is Genio Technologies' headquarters located?

Genio Technologies' headquarters is located in Tulsa, OK, US.

When was Genio Technologies' last funding round?

Genio Technologies' most recent funding round was for $1.3M (USD) in January 2020.

How much has Genio Technologies raised to-date?

As of Jan 23, 2020, Genio Technologies has raised a total of $1.3M (USD).

How many employees does Genio Technologies have?

Genio Technologies has 6 employees as of Feb 4, 2024.

Genio Technologies - Classification

Industry
  • Hardware
Ownership
  • Private
  • Venture Capital
Technology
  • Analytics
  • Machine Learning
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cancer Diagnostics
Tags
  • Biotech
  • Data
  • Healthcare
  • Healthtech
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7372Prepackaged Software
Show 6 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7371Computer Programming Services